Literature DB >> 11259192

An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.

A L Pacchia1, M E Adelson, M Kaul, Y Ron, J P Dougherty.   

Abstract

Lentiviral vectors based on human immunodeficiency virus type 1 (HIV-1) possess the ability to deliver exogenous genes to both dividing and nondividing cells and to subsequently establish a stable provirus in these target cells, which can allow long-term expression of the transferred gene. Herein we describe a stable packaging cell line that is devoid of HIV-1 tat, vif, vpr, vpu, and nef. In order to avoid any risk of cytotoxicity associated with constitutive expression of HIV-1 protease or the VSV-G envelope protein, transcription of the packaging and envelope constructs was tightly controlled by employing the ecdysone-inducible system. Using this cell line, we have been able to consistently generate concentrated pseudotyped vector virus stocks with titers in the range of 10(8) IU/ml, which can efficiently transduce actively dividing and growth-arrested cells in vitro. This novel packaging cell line for lentiviral vectors facilitates the production of high-titer virus stocks in the absence of replication-competent virus and provides us with an important tool for use in future gene transfer studies. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259192     DOI: 10.1006/viro.2000.0787

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

Review 1.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

3.  Human immunodeficiency virus type 1 latency model for high-throughput screening.

Authors:  Sofiya Micheva-Viteva; Annmarie L Pacchia; Yacov Ron; Stuart W Peltz; Joseph P Dougherty
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Efficient large volume lentiviral vector production using flow electroporation.

Authors:  Scott R Witting; Lin-Hong Li; Aparna Jasti; Cornell Allen; Kenneth Cornetta; James Brady; Rama Shivakumar; Madhusudan V Peshwa
Journal:  Hum Gene Ther       Date:  2011-10-24       Impact factor: 5.695

5.  Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome.

Authors:  Javier Ortego; David Escors; Hubert Laude; Luis Enjuanes
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.

Authors:  Robert E Throm; Annastasia A Ouma; Sheng Zhou; Anantharaman Chandrasekaran; Timothy Lockey; Michael Greene; Suk See De Ravin; Morvarid Moayeri; Harry L Malech; Brian P Sorrentino; John T Gray
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

7.  Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.

Authors:  Martin E Adelson; Annmarie L Pacchia; Malvika Kaul; Robert F Rando; Yacov Ron; Stuart W Peltz; Joseph P Dougherty
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

8.  The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy.

Authors:  Preetha Biswas; Xi Jiang; Annmarie L Pacchia; Joseph P Dougherty; Stuart W Peltz
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 9.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.